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Background/Objectives: Recently, ﬁbrotic diseases such as hypertrophic scar, keloid, and scleroderma
have been treated with UV-A1 radiation with encouraging results. However, conventional UV light
sources are bulky and expensive. In this study, we aimed to verify the effectiveness of a portable UV-A1
radiation device in treating hypertrophic scars.
Materials and methods: A light-emitting diode array that emitted 365 ± 5 nm (UV-A1) was used to
irradiate ﬁbroblasts and hypertrophic scar in a rabbit model.
Results: In cell cultures, UV-A1 light exposure inhibited post-wound cell migration and reduced the total
amount of soluble collagen production in ﬁbroblasts. Type I collagenase production and its activity
increased after treatment. On the rabbit ear, UV-A1 light irradiation reduced the thickness of hyper-
trophic scars, conﬁrming the antiﬁbrotic effect in vivo.
Conclusion: These results support the potential of a portable UV-A1 light device in treating hypertrophic
scar.
Copyright © 2014, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Fibrotic diseases in humans, including lung ﬁbrosis,1 liver
cirrhosis,2 scleroderma,3 and keloid,4e6 occur as a result of depo-
sition of collagen in tissues or organs due to an imbalance of
ﬁbrogenesis and ﬁbrolysis. No effective cure is available to treat
these ﬁbrotic diseases. Immunosuppressive agents are usually
recommended but they may have signiﬁcant adverse effects.1 For
skin ﬁbrosing diseases, a safer and effective treatment is UV irra-
diation. UV-A light is an electromagnetic radiation with a wave-
length of 320e400 nm. Phototherapy with UV-A to treat different
skin diseases is usually accompanied by a systemic or topical
photosensitizer to enhance the efﬁcacy of the irradiation.7 The
development of a lamp emitting radiation predominantly in the
long-wavelength UV-A1 (340e400 nm), was described in 1981.8y have no ﬁnancial or non-
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logy, National Cheng-Kung
i Road, Tainan 704, Taiwan.
Dr.Kentwwong@gmail.com
cal Association. Published by ElsevHigh-dose-UV-A1 irradiation without photosensitizer emerged a
decade later to treat atopic dermatitis.9,10
Hypertrophic scars and keloid result from excessive extracel-
lular matrix deposition in the dermis after wound healing.6 Hy-
pertrophic scars are limited to the wound area and usually resolve
spontaneously with time. Keloid is deﬁned as scar tissues growing
beyond original wounds and is challenging to treat. Large scars may
cause disﬁguration and loss of function due to scar contracture.
Both scars may be complicated with pruritus and pain.11 Traditional
scar treatments include pressure garments, silicone gel sheeting,
silicone cream and gel, local steroid injection, and excision and
repair with/without skin graft and/or radiation.5,12 Pressure gar-
ments are inconvenient and uncomfortable especially in tropical
and subtropical countries due to humid and hot weather. Surgical
removal of keloid, although temporarily rewarding, is almost
invariably followed by even more aggressive regrowth of scar tis-
sue.12 The combination of radiation and surgery provides a higher
success rate to cure keloid. However, long-term safety has not been
established and invasive tumor may develop after this regimen.13
Intralesional steroid injections are probably the most common
therapy clinically. Many patients are reluctant to undergo this
painful therapy, especially for children and patients with large
keloid.5,14 Recently, UV-A1 has been used in treating localized15 and
generalized scleroderma16 with encouraging results. UV-A1ier Taiwan LLC. All rights reserved.
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human ﬁbroblasts in vitro.17 Asawanonda et al18 demonstrated that
UV-A1 with a cumulative dose of 2860 J/cm2 was helpful in treating
keloid in a 37-year-old man. The results were not supported in a
subsequent study in which three keloid patients showed no
response after receiving UV-A1 irradiation with cumulative doses
of 1500e1800 J/cm2.19 Moreover, the application of UV-A1 therapy
is limited to a few centers because of the large size and high cost of
the machines.20
To develop the application of UV therapy for larger groups of
patients, smaller and more economical UV devices are in demand.
One potential candidate is the light-emitting diode (LED) light
source which has the advantages of portability, high luminance, a
relatively narrow spectrum, long lifespan, and low cost. In fact,
LEDs in the visible spectrum have been applied to phototherapy in
several other skin diseases such as wound healing,21 acne,22 and
photodynamic therapy.23 In this study, we tested the efﬁcacy of UV-
A1 LEDs in treating hypertrophic scar on rabbit ear.
Materials and methods
UV-A1-LED light source
A commercial UV-A1-LED light source (Figure 1B) composed of 18
LEDs (LH365BG02) in a 5-cm circle was bought from ClearstoneFigure 1 Traditional UV-A1 bed (A) (Sellamed 24000; Sellas Medizinische Ger€ate GmbH, Enn
2014). The size is 235 cm  137 cm  210 cm and weight 500 kg. UV-A1-LED light source (B)
365 ± 5 nm with a total optical power of 4500 mW. Size: 24.1 cm  17.2 cm  20.3 cm anTechnologies Inc. (Hopkins, MN, USA). This device emits wave-
lengths of 365 ± 5 nm with a total optical power of 2500 mW. The
uniformity and intensity of light was conﬁrmed by an UV-A meter
(UV-Meter HighEnd, Hoenle UV Technology Inc., Grafelﬁng, Ger-
many). The light intensity was set at 30 mW/cm2 for in vitro and
100mW/cm2 for in vivo experiments by adjusting the distance from
the light source to the treated surface. An electric fan was used to
disperse heat during irradiation.
Cells
Human fetal skin ﬁbroblasts (WS1)24 were obtained from the Bio-
resource Collection and Research Center (BRCB, Taipei, Taiwan) and
were maintained in Eagle's Minimum Essential Medium supple-
mented with 10% fetal bovine serum, 2.5 mMHEPES, and 100 U/mL
penicillin/streptomycin at 37C in 5% CO2.
UV-A1 phototoxicity in ﬁbroblasts
The purpose of the study was to determine the optimal UV-A1 dose
to inhibit scar formationwithout damaging cells. The phototoxicity
of UV-A1 in ﬁbroblasts was determined by exposing cells to
different UV doses after seeding 1 104 cells in 100 mL medium per
well of a 96-well plate for 16 hours. Cell survival was determined
with WST-1 assay25 24 hours after treatment. The irradiation doseepetal, Germany; http://www.sellas.de/index.php?id¼37&L¼2; date accessed: May 23,
used in this study was composed of 18 LEDs in a 5-cm circle and emitted wavelengths of
d weight 4.1 kg. LED ¼ light-emitting diode.
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experiments.
Total collagen, collagenase I production, and collagenase
activity
Supernatant was collected 24 hours after treating cells with UV-A1.
Total soluble collagen content in the supernatant was measured
with Sircol assay (Biocolor Ltd., Carrickfergus, Antrim, UK).26 Since
type I collagen is overproduced in keloid and hypertrophic scar,6 we
measured type I collagenase (MMPI)26 and its activity27 in the su-
pernatant with ELISA kits (Biotrak-ELISA System, Amersham, GE
Inc., Piscataway, NJ, USA) following themanufacturer's instructions.
Cell migration
Cell migration was assessed by creating a 0.5-mm wound with a
200-mL pipette tip on the center of a conﬂuent cell sheet.27 Cells
were treated with mitomycin C (10 mg/mL) to inhibit cell prolifer-
ation for 2 hours at 37C and 5% CO2 prior to scratching the cell
sheet. The damaged area was recorded over time with a digital
camera coupled to a microscope and analyzed with Image-J soft-
ware (National Institutes of Health, Bethesda, MD, USA).
UV-A1 effect on hypertrophic scar in rabbit ear
Five full-thickness dermal wounds were created on the ventral site
of each ear of three New Zealand white rabbits (3e6months of age,
2e2.5 kg) with a 6-mm punch.28 All study protocols were in
compliance with and approved by the Animal Center Review Board
of the institution. Wounds were left open and hypertrophic scars
formed in 28 days. Scars on one ear were irradiated every 2 days
with 150 J/cm2 at 100 mW/cm2 UV-A1 for 30 days (total: 2250 J/Figure 2 Cell survival, total collagen production, type I collagenase (MMP-I) titer, and type
exposed to light dose higher than 9 J/cm2 (A). The total collagen production decreased 4
collagenase in supernatant increased around 40% (C) and its activity increased around 20
metalloproteinase-1.cm2) while the scars on the other ear served as a control. The scar
thickness was measured with a caliper (Mitutoyo Inc., Kawasaki,
Japan) and digital images were recorded and assessed by observers
blinded to the study.
Statistical analysis
One-way analysis of variance (ANOVA) was used for multiple group
comparisons. Unpaired Student's t test was used to compare be-
tween two groups. Dose dependence was analyzed by linear
regression. At least two separate independent experiments in
triplicate were done for the in vitro studies. A p value <0.05 was
considered statistically signiﬁcant.
Results
UV-A1 inhibits collagen production and enhances collagenase I
secretion
As expected,29 the phototoxicity of UV-A1 on human ﬁbroblasts
was dose dependent (Figure 2A), with a lethal dose beginning at 9 J/
cm2.We therefore adopted UV light doses <9 J/cm2 in the rest of the
experiments. The main product of ﬁbrosis, the total collagen con-
tent, was reduced by UV-A1 irradiation (40% at 3 J/cm2, p < 0.05;
70% at 6 J/cm2, p < 0.001, one-way ANOVA; Figure 2B). UV-A1
irradiation enhanced collagenase I production in a dose-
dependent manner (Figure 2C) and improved the enzyme activity
signiﬁcantly (Figure 2D). The collagenase I in the supernatant
increased 33% at 3 J/cm2 and 44% at 6 J/cm2 compared to the control
(p < 0.05, one-way ANOVA; Figure 2C). The enzyme activity
increased 25% at 3 J/cm2 (p < 0.01) and 21% at 6 J/cm2 (p < 0.05),
respectively (Figure 2D). These results demonstrated the anti-
ﬁbrotic effects of UV-A1.I collagenase activity after UV-A1 exposure. Signiﬁcant cell death occurred after being
0e70% compared to the control (B) after irradiation with nonphototoxic doses. The
% (D) compared to the control. *p < 0.05; **p < 0.01; ***p < 0.001. MMP-1 ¼ matrix
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Fibroblast migration may also play a critical role in ﬁbrotic diseases
such as active keloid. In the clinic, keloid spreads beyond the
margins of the original wound. The ﬁbroblasts proliferate, migrate,
and lay down collagen on their path and generate tongue-like
ﬁbrotic tissue advancing edges under the microscope.4 Fibroblast
migration induced by an artiﬁcial wound in culture was similarly
inhibited in a dose-dependent manner by UV-A1 irradiation
(Figure 3).
Rabbit ear scarring is inhibited by UV-A1 irradiation
On the rabbit ear, the minimal dose of UV radiation producing er-
ythema was 150e200 J/cm2 (data not shown). We therefore chose
150 J/cm2 to test the effect on the scar (n ¼ 15). After multiple
treatments (irradiation every 2 days, cumulative dose 2250 J/cm2),
scar tissue became thinner on Day 20 after the onset of irradiation
and the change of thickness became statistically signiﬁcant on Day
84 (Figure 4). The treated scars continued to resolve even after UV
therapy was discontinued. The time course of the responses
observed in this study (35e84 days after onset of treatment) was
consistent with the slow response of ﬁbrotic tissues to other forms
of treatment.5Figure 3 Effects of UV-A1 on ﬁbroblast migration. Fibroblasts were exposed to
different UV-A1 doses after a wound was created on the center of the cell sheet. Cell
migration was inhibited by UV-A1 irradiation in a dose-dependent manner (A). Data
are mean ± standard error of three separate experiments performed in triplicate
(*p < 0.05) (B).
Figure 4 Efﬁcacy of UV-A1 irradiation on hypertrophic scars. Five hypertrophic scars
were created on each ear in three New Zealand white rabbits. Control scar (A) was
hypertrophic while treated scars were reduced in thickness (B) after treatment. The p
value was <0.05 compared to the control at 84 days and 112 days after wounding (C).
Bar ¼ 6 mm.Discussion
Our study demonstrates the beneﬁcial effects of LED UV-A1 irra-
diation on hypertrophic scar. The efﬁcacy of this small portable,
inexpensive LED light source on treating ﬁbrosis tissue is compa-
rable to a large UV-A1 machine.18 Various UV-A1 sources are
available, such as ﬂuorescent lamp cubicles which allow only low
(10e30 J/cm2) to medium (40e70 J/cm2) individual treatment
doses to be administered. High-output metal halide sources allow
high doses (up to 130 J/cm2) for a single treatment session. Low and
mediumUV-A1 dose showsminimal to moderate effects in treating
atopic dermatitis, and high UV-A1 dose provides better control of
the disease. High UV-A1 dose is particularly promising for localized
scleroderma including widespread, pansclerotic, and linear mor-
phea because there is no reliable treatment available.30 Setge et al31
showed that a high dose (130 J/cm2 for 30 times, cumulative dose
3900 J/cm2, n ¼ 10) was more effective than a low dose (20 J/cm2,
cumulative dose 600 J/cm2, n ¼ 7) of UV-A1 in treating 17 patients
with localized scleroderma. Four of 10 patients in the high-dose
group showed complete clearance. A higher UV-A1 dose is also
required for treating keloid.18 The higher dose required for treating
ﬁbrosing diseases suggests the existence of one effective threshold
dose of UV-A1 irradiation, probably higher than 2250 J/cm2. The
thicker collagenous tissue may need a higher light dose to achieve
therapeutic results. It is also likely that an optimal dose may exist
along with a temporal course of treatment in relation to the onset
time of scar tissue. In the present study, hypertrophic scar was
treated after it was established. Whether early UV-A1 intervention
prevents hypertrophic scar formation or enhances wound healing
remains to be explored.
This rabbit scar model parallels hypertrophic scar in humans
and has been used to study potential therapeutic modalities.28
However, the model cannot study the safety of chronic UV-A1
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be determined before extensive use of UV-A1 on humans.9,30 The
major acute adverse effects of UV-A exposure are erythema and
pigmentation. The erythema response can be avoided by giving a
minimal erythema dose test before treatment and adjusting doses
according to the response. Pigmentation of the skin is reversible.
Themajor potential chronic adverse effects are photoaging and skin
cancer.32,33 Although it is unclear whether or not UV-A1 increases
the risk of melanoma, a case of cutaneous melanoma diagnosed
after 18 months intensive UV-A1 and psoralen UV-A (PUVA) for
urticaria pigmentosa has been reported. In this report, the total
dose of UV-A1 was 910 J/cm2, while the total dose of PUVA was
2144 J/cm2. A role for UV-A in causing malignant melanoma cannot
be excluded.34 However, UV-A irradiation causing skin cancer is not
detected in persons who are pigmented, tan easily, or are of Asian
or African ancestry (Fitzpatrick Skin Type IV or higher). The effec-
tive cumulative dose of UV-A1 required for treating keloid in our
study was ~2000 J/cm2 without psoralen. This treatment may be
relatively safe in our population. Similarly, the risk of UV-A1
inducing non-melanoma skin cancers, particularly squamous cell
carcinoma, is not known, although UV-A induces squamous cell
carcinoma-like tumors in mice.32 Another limitation of our study
was the lack of ﬁbroblasts from human hypertrophic scar for
mechanistic studies. Nevertheless, WS1 ﬁbroblasts are a commer-
cial cell line derived from 12-week gestation fetal skin. These cells
are highly proliferative and senescent around 70 passages. It has
been widely used as a model in wound healing studies.35 Hyper-
trophic scar, unlike keloid, usually spontaneously resolves with
time. In case of limited resources of human tissue, using WS1 ﬁ-
broblasts may be an alternative model.
In summary, we showed in in vitro and in vivo systems that UV-
A1 irradiation using an LED light source was effective in treating
hypertrophic scars. However, the long-term side effects need to be
explored in future experiments.
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